INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Alternative Medicine Biomolecules in the Management of Gastrointestinal Tract Infections

Chakresh Madhav Mishra*, Pramod Kumar Mishra, Sujeet Pratap Singh, Dr. Tarkeshwar Prasad Shukla

Scpm college of pharmacy haripur gonda.

ARTICLE INFO

Published: 16 Nov 2026
Keywords:
gastrointestinal infections, phytomedicine, berberine, allicin, curcumin, Triphala, antimicrobial resistance, drug delivery
DOI:
10.5281/zenodo.24279311

ABSTRACT

Gastrointestinal tract (GIT) infections range from self-limiting diarrhoeal illnesses to serious diseases associated with dehydration, intestinal injury, systemic complications, or outbreaks. The supplied review article highlights antimicrobial resistance among enteric pathogens and the limitations of indiscriminate antibiotic exposure, including disruption of the normal intestinal microbiota. Against this background, plant-derived biomolecules and traditional formulations have attracted research interest as possible antimicrobial or supportive agents. This project reviews four principal examples discussed in the source article: berberine, an isoquinoline alkaloid associated with Berberis aristata and Coptis chinensis; allicin, an organosulfur compound formed when garlic tissue is disrupted; curcumin, a polyphenol from Curcuma longa; and Triphala, a traditional formulation containing Phyllanthus emblica, Terminalia chebula, and Terminalia bellirica. Proposed mechanisms include effects on bacterial membranes, efflux pumps, virulence and biofilm pathways, inflammatory signalling, and mucosal protection. The report also considers key translational limitations: variable phytochemical content, poor aqueous solubility or bioavailability for some compounds, possible interactions, and a shortage of consistent clinical standardization. Nanocarriers such as liposomes, solid lipid nanoparticles, and polymeric nanoparticles are discussed as research strategies that may improve delivery. The evidence described in the supplied article is promising but should not be interpreted as proof that these agents can replace established treatment. Further standardized preclinical and clinical studies are needed.

***Corresponding Author:** Chakresh Madhav Mishra
Address: Scpm college of pharmacy haripur gonda
Email ✉: chakreshmadhavmishra@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

INTRODUCTION

The gastrointestinal tract is responsible for digestion, absorption, fluid and electrolyte balance, and interaction with a large microbial community. Infection can disturb these functions and may present as diarrhoea, vomiting, abdominal cramps, fever, dysentery, or systemic illness. The clinical severity depends on the causative organism, the amount of exposure, host immunity, age, hydration status, and access to appropriate care.

The supplied article identifies Helicobacter pylori, Salmonella enterica, Shigella species, pathogenic Escherichia coli, Vibrio cholerae, Campylobacter jejuni, and Clostridioides difficile among organisms relevant to the discussion of enteric infection and antimicrobial resistance. These organisms differ in transmission, disease mechanism, and treatment requirements; therefore, a single botanical product cannot be assumed to act equally against all of them.

Antibiotics and other conventional medicines remain important when indicated. However, inappropriate antibiotic use can promote resistance and may alter the protective gut microbiota. The resulting interest in phytomedicine is best understood as a search for additional pharmacological leads, complementary strategies, and better delivery systems—not as a reason to delay diagnosis or replace evidence-based care.

Plant materials contain chemically diverse constituents, including alkaloids, polyphenols, organosulfur compounds, tannins, and terpenoids. Some show antimicrobial activity in laboratory models, while others may affect inflammatory responses or mucosal function. Research must distinguish laboratory activity from clinical benefit, because an effect in a test tube does not establish that a safe and effective concentration can be achieved in the human intestine.

This project develops the themes of the supplied review article into a structured pharmacy report, emphasizing mechanisms, formulation science, standardization, and cautious interpretation of evidence.

2. AIM AND OBJECTIVES

2.1 Aim

To review selected alternative-medicine biomolecules and traditional plant formulations discussed in the supplied article for their potential role in the management of gastrointestinal tract infections.

2.2 Objectives

To describe the clinical and public-health importance of gastrointestinal infections.

To summarize the antimicrobial-resistance concerns highlighted in the source article.

To introduce berberine, allicin, curcumin, and Triphala, including their botanical sources and reported activities.

To explain proposed mechanisms involving bacterial membranes, efflux pumps, biofilms, virulence factors, and host inflammatory pathways.

To compare the major compounds by source, target organisms reported in the article, and proposed mechanisms.

To discuss solubility, bioavailability, stability, quality-control, safety, and standardization challenges.

To outline the potential role of nanocarriers and other delivery approaches in future research.

To identify evidence gaps and recommend cautious, evidence-based development.

2.3 Scope of the project

The report is a literature-based academic synthesis. Its scope is limited to the compounds and themes present in the supplied review article, with general explanatory context added for educational clarity. It does not provide patient-specific dosing, treatment protocols, or a claim that any discussed product is an approved substitute for standard therapy.

3. REVIEW METHODOLOGY

The source article describes a systematic review protocol using PubMed, ScienceDirect, Google Scholar, and the Cochrane Library, with literature published up to 2026. Search concepts included alternative medicine, phytopharmaceuticals, gastrointestinal

infections, antimicrobial mechanisms, berberine, allicin, curcumin, and enteric pathogens. Boolean operators and Medical Subject Headings (MeSH) terms were reported as part of the search approach.

According to the supplied article, inclusion criteria covered peer-reviewed original research, in-vitro and in-vivo pharmacological evaluations, randomized controlled trials, and authoritative clinical reviews published in English. Articles focused only on structural botany without pharmacological validation, or poorly characterized crude mixtures without chemical profiling, were excluded.

3.1 Information extracted

Primary phytochemical or formulation identity and botanical source.

Target organisms and reported antimicrobial effects.

Proposed mechanisms of action, including membrane effects and efflux-pump inhibition.

Safety and toxicological considerations where reported.

Clinical or preclinical outcomes and formulation-related limitations.

3.2 Limitations of the available source

The supplied article does not provide a complete reproducible search log, the number of records retrieved and screened, a flow diagram, detailed risk-of-bias assessments, or full study-level MIC and clinical outcome tables. Its reference list also includes sources on broader pharmaceutical topics. Therefore, this expanded project preserves the article's central framing but does not claim to independently reproduce or validate a full systematic review. Specific clinical conclusions require verification against primary studies.

4. OVERVIEW OF GASTROINTESTINAL TRACT INFECTIONS

4.1 Clinical spectrum

GIT infections may cause mild, short-duration symptoms or severe disease. Acute gastroenteritis commonly involves diarrhoea and vomiting, which can lead to dehydration and electrolyte disturbance. Dysentery may involve blood or mucus in stool and requires clinical evaluation. Some pathogens can produce systemic illness or complications beyond the intestinal lumen.

4.2 Important pathogens mentioned in the article

Pathogen	General relevance	Consideration for research
Helicobacter pylori	Associated with chronic gastric infection and ulcer-related disease.	Evaluate eradication outcomes and distinguish direct antibacterial effects from anti-inflammatory effects.
Salmonella enterica	Includes enteric and foodborne disease-causing strains.	Resistance patterns and clinical presentation vary by strain and setting.
Shigella species	Can cause inflammatory diarrhoea and dysentery.	Susceptibility testing and clinical severity matter.
Pathogenic E. coli	Different pathotypes cause different diarrhoeal syndromes.	Results should identify the pathotype and toxin-related endpoint.
Vibrio cholerae	Can cause profuse watery diarrhoea and rapid fluid loss.	Rehydration is essential; laboratory antimicrobial effects alone are insufficient evidence.
Campylobacter jejuni	A foodborne cause of gastroenteritis.	Resistance and local clinical guidance influence treatment.
Clostridioides difficile	Can cause antibiotic-associated diarrhoea and colitis.	Microbiome effects and recurrence outcomes are important endpoints.

4.3 Transmission and prevention

Enteric pathogens may spread through contaminated food or water, inadequate hand hygiene, person-to-person contact, and exposure to infected animals or environments. Prevention relies on safe water, sanitation, handwashing, food hygiene, vaccination where recommended, and appropriate infection-control

practices. These measures remain central regardless of whether new phytochemicals are developed.

4.4 Antimicrobial resistance and microbiota

Antimicrobial resistance occurs when microorganisms become less susceptible to medicines that previously inhibited them. The source article emphasizes multidrug-resistant enteric pathogens and describes how indiscriminate antibiotic use can contribute to selection pressure. Antibiotics can also disturb commensal organisms that support metabolism and intestinal barrier function. The relationship is complex: natural compounds may also affect beneficial microbes, so selectivity and microbiome outcomes must be measured rather than assumed.

5. ALTERNATIVE MEDICINE AND PHYTOMEDICINE

5.1 Definition and scope

Alternative medicine is a broad term for health practices outside the dominant conventional medical system; complementary medicine is generally used alongside conventional care. Phytomedicine refers to medicinal preparations derived from plants. In pharmaceutical research, a plant-derived product must be characterized by its identity, chemical composition, dose, quality, stability, and safety. Traditional use can provide useful leads, but it is not by itself proof of clinical efficacy.

5.2 Why natural biomolecules are investigated

Plant secondary metabolites are structurally diverse. A molecule may interact with several bacterial or host pathways, and combinations of constituents may show additive, synergistic, or antagonistic effects. Multi-target activity is a hypothesis to investigate, not a guarantee that resistance will not develop. Reproducible assays and suitable controls are needed to determine the true activity of each substance.

5.3 From traditional use to pharmaceutical evidence

Botanical authentication and traceable sourcing of the plant material.

Extraction and purification using documented methods.

Chemical fingerprinting and quantification of marker compounds.

Standardized microbiological tests with appropriate positive and negative controls.

Toxicity, pharmacokinetic, interaction, and microbiome assessments.

Well-designed clinical studies using meaningful patient outcomes.

5.4 Evidence hierarchy

Evidence may range from ethnobotanical reports and in-vitro screening to animal studies, early human trials, and well-designed randomized controlled trials. Each level answers different questions. Laboratory inhibition supports biological plausibility but cannot establish a treatment recommendation. Human studies must address appropriate comparators, sample size, dosing, adverse events, and clinically meaningful outcomes.

6. MAJOR BIOMOLECULES AND FORMULATIONS

6.1 Berberine: an isoquinoline alkaloid

The source article identifies berberine as an isoquinoline alkaloid associated with Berberis aristata and Coptis chinensis. It notes traditional use for infectious diarrhoea and dysentery and reports activity against organisms such as Vibrio cholerae and enterotoxigenic E. coli. The article further describes possible inhibition of bacterial FtsZ protein polymerization and efflux pumps.

FtsZ is involved in bacterial cell division, making it an attractive target for antibacterial research. Efflux pumps, by contrast, can reduce intracellular concentrations of some antimicrobial agents by transporting them out of bacterial cells. A compound that inhibits an efflux system could potentially increase exposure to another agent, but this effect must be confirmed for each organism and drug combination.

Development considerations include dose consistency, solubility, absorption, metabolism, interactions with other medicines, and the difference between purified berberine and a crude plant extract. The presence of a compound in a traditional plant does not mean that all

preparations deliver the same concentration or safety profile.

6.2 Allicin: an organosulfur compound

Allicin is described in the source article as a compound formed when garlic (Allium sativum) tissue is mechanically disrupted, allowing alliin and the enzyme alliinase to interact. The article characterizes allicin as volatile and lipophilic and discusses its activity against Gram-positive and Gram-negative organisms, including H. pylori and Salmonella enterica.

Allicin can react with thiol-containing groups in proteins, a chemical property relevant to its proposed antimicrobial effects. However, its instability and reactivity complicate measurement of the active dose. Processing, storage, preparation, and gastrointestinal conditions may influence the amount of allicin available at the target site. Garlic food use and a concentrated standardized medicinal preparation are not interchangeable exposures.

6.3 Curcumin: a polyphenol from turmeric

Curcumin is the principal lipophilic polyphenol discussed in the article and is obtained from the rhizome of Curcuma longa. The source emphasizes dual antimicrobial and anti-inflammatory characteristics and describes potential relevance to H. pylori colonization. Proposed mechanisms include interference with quorum sensing and modulation of NF-κB-related inflammatory signalling.

Curcumin has important formulation limitations, especially poor aqueous solubility and rapid metabolism, which can restrict exposure. Its observed biological effects may depend on formulation, concentration, and experimental model. The project therefore treats curcumin as a research candidate rather than an established stand-alone therapy for gastrointestinal infection.

6.4 Triphala: a traditional polyherbal formulation

Triphala is described as a mixture of equal parts of Phyllanthus emblica (Amla), Terminalia chebula (Haritaki), and Terminalia bellirica (Bibhitaki). The source article reports broad antibacterial potential and antioxidant or mucosal-protective activity. Because Triphala contains many constituents, its biological effects cannot automatically be attributed to one molecule.

A polyherbal formulation creates specific quality-control challenges: the identity and proportion of each plant must be verified, raw materials vary by growing conditions and harvest, and processing can alter chemical profiles. A reproducible product requires specifications for botanical identity, marker compounds, contaminants, microbial quality, and batch-to-batch consistency.

6.5 Summary of selected agents

Agent	Source in article	Activity/mechanism reported in source	Key limitation
Berberine	Berberis aristata; Coptis chinensis	Activity against selected enteric pathogens; efflux-pump and FtsZ-related effects.	Exposure, interactions, and standardized dose need evaluation.
Allicin	Allium sativum	Reacts with bacterial SH groups; effects on RNA/protein synthesis are discussed.	Chemical instability and variable content.
Curcumin	Curcuma longa	Antimicrobial and anti-inflammatory effects; quorum-sensing/NF-κB pathways.	Poor aqueous solubility and rapid metabolism.
Triphala	P. emblica; T. chebula; T. bellirica	Broad antibacterial and antioxidant/mucosal-protective potential.	Complex mixture and standardization challenges.

7. PHARMACOLOGICAL MECHANISMS OF ACTION

7.1 Bacterial membrane disruption

Bacterial membranes maintain ionic gradients, transport nutrients, and support energy generation. Certain lipophilic compounds may partition into membrane structures and increase permeability. The source article describes membrane disruption as a mechanism that can cause loss of essential cellular contents and disturbance of the proton motive force. The magnitude of this effect depends on compound, concentration, organism, and assay conditions.

7.2 Efflux-pump inhibition

Efflux systems can transport structurally diverse compounds out of bacterial cells and contribute to reduced susceptibility. The article identifies the AcrAB-TolC system as an example in Gram-negative bacteria and discusses berberine as a possible natural efflux-pump inhibitor. Confirmatory experiments should measure intracellular accumulation, transporter activity, and antibiotic susceptibility while ruling out nonspecific membrane damage.

7.3 Interference with bacterial division

The supplied article associates berberine with inhibition of FtsZ protein polymerization. Since FtsZ helps organize the bacterial division apparatus, disrupting its function may affect cell division. Mechanistic confirmation requires biochemical assays, microscopy or other suitable cellular studies, and comparisons with known controls. The presence of a proposed target should not be confused with proven clinical effectiveness.

7.4 Quorum sensing, virulence, and biofilms

Quorum sensing is a form of bacterial communication that can regulate collective behaviours, including virulence-factor production and biofilm development. Biofilms are structured communities embedded in a matrix that may reduce susceptibility to antimicrobials and host defences. The source article discusses curcumin-related disruption of quorum-sensing pathways and down-regulation of enterotoxin expression. These claims need organism-specific validation because quorum-sensing systems differ among species.

7.5 Reaction with bacterial thiol groups

The article describes allicin as reacting with bacterial sulfhydryl (SH) groups and affecting RNA or protein synthesis. Thiol chemistry can influence the function of many enzymes and proteins. The same reactivity may also affect host molecules, which makes selectivity and toxicity assessment essential. Antimicrobial potency alone is insufficient without a therapeutic window.

7.6 Host immunomodulation and cytoprotection

The source article proposes that curcumin and Triphala may reduce inflammatory signalling associated with NF-κB and pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. It also discusses possible support of mucosal goblet-cell function and mucin secretion. Inflammation is part of host defence as well as a cause of tissue injury; suppressing it too strongly could be harmful in some infections. Studies should measure both pathogen control and host outcomes.

7.7 Mechanism-to-outcome translation

Mechanistic experiments help explain how a compound may work, but the clinical outcome depends on achievable concentration, exposure time, site of infection, host factors, and pathogen susceptibility. A useful development pathway links target engagement to reproducible microbiological activity, animal-model results where appropriate, pharmacokinetics, safety, and finally controlled human studies.

Project Report | Page

SCPM COLLEGE OF PHARMACY, GONDA, UTTAR PRADESH

8. COMPARATIVE PHARMACOLOGICAL PROFILE

Parameter	Berberine	Allicin	Curcumin	Triphala
Class	Alkaloid	Organosulfur compound	Polyphenol/curcuminoid	Polyherbal mixture
Plant source	Berberis aristata; Coptis chinensis	Allium sativum	Curcuma longa	P. emblica, T. chebula, T. bellirica
Targets discussed	V. cholerae, E. coli, Shigella spp.	H. pylori, Salmonella enterica	H. pylori, C. difficile	E. coli, S. aureus, S. typhi
Proposed actions	FtsZ-related effects; efflux inhibition	Thiol reaction; interference with bacterial processes	Quorum sensing; inflammatory signalling	Cell-wall-related effects; antioxidant/mucosal support
Formulation concern	Dose/exposure and interaction evaluation	Instability and volatility	Poor water solubility; rapid metabolism	Complexity and batch variability
Development priority	Standardized assays and exposure data	Stabilization and reliable quantification	Solubility and targeted delivery	Botanical authentication and fingerprinting

8.1 Interpretation

The table summarizes the source article's framing rather than ranking the compounds by clinical effectiveness. The agents differ substantially in chemistry, stability, and evidence base. Direct comparison requires standardized concentrations, matched organisms and assays, appropriate controls, and reporting of both activity and toxicity. The article does not provide enough consistent study-level numerical data to establish a definitive potency ranking.

8.2 Suggested endpoints for future studies

Minimum inhibitory concentration and minimum bactericidal concentration using validated methods.

Time-kill curves and repeatability across multiple isolates.

Biofilm biomass, viability, and virulence-factor assays where relevant.

Cytotoxicity in appropriate intestinal cell models.

Stability and release testing under simulated gastrointestinal conditions.

Microbiome composition and function in suitable preclinical or clinical designs.

Patient-centred outcomes, adverse events, and recurrence in clinical trials.

9. BIOPHARMACEUTICAL AND SAFETY CHALLENGES

9.1 Solubility and bioavailability

Bioavailability describes the fraction of a dose that reaches systemic circulation or, for local intestinal therapies, the fraction available at the intended site. A locally acting intestinal compound may not require high systemic absorption, but it must remain stable and available where the pathogen or inflammatory process is located. The source article particularly highlights curcumin's poor aqueous solubility and rapid first-pass metabolism.

9.2 Chemical and physical stability

Some natural compounds are sensitive to light, heat, oxygen, pH, moisture, or enzymatic degradation. Allicin's reactivity and volatility make preparation and storage important. A pharmaceutical formulation should define acceptable storage conditions, packaging, shelf life, and a validated analytical method capable of measuring the active constituent or suitable marker.

9.3 Botanical variability and standardization

Chemical composition can vary with species, plant part, soil, climate, geographic origin, harvest season, drying, extraction solvent, and processing. For a polyherbal preparation, every component introduces another source of variability. Standardization may

combine botanical authentication, chromatographic fingerprints, marker-compound assays, microbial limits, heavy-metal and pesticide testing, and checks for adulterants.

9.4 Safety and interactions

"Natural" does not mean risk-free. Concentrated extracts may produce adverse effects, interact with prescribed medicines, or be unsuitable for particular groups. Risk assessment should consider dose, duration, route, pregnancy and lactation where relevant, liver and kidney function, and concomitant medicines. The source article characterizes the toxicological profiles as promising, but the supplied text does not provide detailed study-level safety tables; therefore, safety cannot be generalized to all products or doses.

9.5 Quality control and manufacturing

Verify identity, purity, and botanical source of incoming materials.

Use validated extraction and manufacturing procedures.

Set specifications for active or marker constituents and degradation products.

Test microbial contamination, relevant chemical contaminants, and adulteration.

Assess batch uniformity, dissolution or release, packaging compatibility, and shelf life.

Maintain traceability and documentation under applicable quality systems.

9.6 Regulatory considerations

Regulatory requirements differ by jurisdiction and by whether a product is classified as a medicine, traditional medicine, supplement, or another category. A claim to treat an infection requires evidence appropriate to that claim. Development should include product-specific quality, safety, and efficacy data and comply with the applicable national requirements. The project does not assign regulatory status to any of the discussed compounds.

10. ADVANCED DRUG DELIVERY AND FUTURE DIRECTIONS

10.1 Liposomes

Liposomes are vesicles formed from lipid bilayers. Depending on their design, they can carry water-soluble or lipid-soluble compounds and may protect sensitive constituents from degradation. For gastrointestinal use, formulation design must consider gastric acidity, bile salts, digestive enzymes, release location, and manufacturing stability.

10.2 Solid lipid nanoparticles

Solid lipid nanoparticles (SLNs) use a lipid matrix to incorporate selected active compounds. They are investigated for improving apparent solubility, protecting labile molecules, and modifying release. Important quality attributes include particle size distribution, surface characteristics, drug loading, encapsulation efficiency, release profile, and physical stability during storage.

10.3 Polymeric nanoparticles

Polymeric nanoparticles can be designed to control release or protect a payload during transit through the gastrointestinal tract. Polymer choice, degradation behaviour, compatibility, and safety need evaluation. A targeted intestinal formulation should demonstrate that the active agent reaches the intended site and improves relevant outcomes compared with an appropriate control.

10.4 Localized and targeted delivery

Targeted delivery to the intestinal lumen or inflamed mucosa may reduce premature degradation and improve local exposure. However, targeting claims require experimental confirmation. Researchers should characterize release under relevant pH and enzyme conditions and measure the distribution of the active compound in suitable models.

10.5 Combination approaches

The source article suggests combining engineered bacteriophages with purified plant biomolecules as a possible research direction for multidrug-resistant infections. Such combinations require careful evaluation

of compatibility, bacterial host range, resistance development, effects on beneficial microbiota, and clinical safety. Potential synergy must be demonstrated experimentally rather than assumed from separate activities.

10.6 Research roadmap

Stage	Key question	Suggested evidence
1. Identity and chemistry	What is the active material?	Botanical authentication, purity, chemical fingerprint.
2. In-vitro testing	Is activity reproducible and selective?	Validated susceptibility assays, cytotoxicity and controls.
3. Formulation	Can the active material be delivered reliably?	Stability, release, particle characterization where relevant.
4. Preclinical evaluation	Does the formulation improve exposure and outcomes?	Pharmacokinetic, safety and disease-model data.
5. Clinical testing	Does it benefit patients safely?	Ethically approved controlled trials with defined outcomes.
6. Quality lifecycle	Can each batch remain consistent?	Specifications, validated methods, ongoing stability and monitoring.

DISCUSSION

The supplied review article presents phytomedicine as a potential source of additional tools for addressing gastrointestinal pathogens and antimicrobial resistance. Berberine, allicin, curcumin, and Triphala illustrate different chemical classes and different research questions: efflux and cell-division effects, thiol reactivity, antimicrobial and inflammatory pathways, and the complexity of polyherbal mixtures.

A major strength of the topic is its integration of pathogen-directed and host-directed effects. In gastrointestinal disease, reducing pathogen burden is not the only relevant outcome; hydration, mucosal integrity, inflammation, and microbiome recovery can also influence recovery. Nevertheless, host modulation must be balanced against the need for effective immune defence, and claims about protecting the microbiome require direct measurement.

The central limitation is the gap between pharmacological plausibility and clinical evidence. A compound can inhibit bacteria at a laboratory concentration that is not achievable in the human gut, may be unstable during digestion, or may cause toxicity at the required exposure. Results from crude extracts cannot be generalized to purified constituents, and findings from one bacterial strain cannot be generalized to every strain or disease syndrome.

Standardization is therefore not a minor manufacturing issue; it is essential to interpret efficacy and safety. Without reliable botanical identity, quantitative chemical profiles, and consistent manufacturing, clinical outcomes cannot be reproduced. Delivery technologies may help address solubility and stability, but a sophisticated carrier does not compensate for weak pharmacology or inadequate safety evaluation.

The source article describes its approach as a systematic review, but the supplied document does not include enough information to independently reproduce the search or assess all included studies. It also provides limited numerical data for direct comparisons. These limitations mean that the present project should be understood as an expanded narrative academic report based on the supplied article, not a new systematic review or a meta-analysis.

11.1 Pharmacy practice implications

Pharmacists can contribute by supporting responsible antimicrobial use, checking for potential interactions, advising patients to seek appropriate medical assessment for severe or persistent symptoms, and explaining that herbal products vary in quality. Patients should not stop prescribed antibiotics or substitute unverified remedies without advice from a qualified clinician. Suspected severe dehydration, blood in stool, high fever, persistent vomiting, or symptoms in vulnerable patients warrant prompt medical evaluation.

11.2 Key knowledge gaps

More transparent study-selection methods and reproducible systematic searches.

Comparable MIC and time-kill data across well-defined clinical isolates.

Product-specific pharmacokinetics and intestinal exposure measurements.

Adequately powered clinical trials with prespecified outcomes.

Longer-term safety, interaction, and microbiome assessments.

Validated manufacturing standards and post-market quality monitoring.

CONCLUSION AND RECOMMENDATIONS

12.1 Conclusion

The supplied review article identifies berberine, allicin, curcumin, and Triphala as promising examples of natural biomolecules or traditional formulations being investigated for gastrointestinal infections. Their proposed actions include effects on bacterial membranes, efflux pumps, cell division, virulence and biofilm pathways, inflammatory signalling, and mucosal protection. These mechanisms provide a rationale for further research into phytomedicine and combination strategies.

Important limitations remain. Poor solubility or bioavailability, chemical instability, botanical variability, incomplete standardization, and limited clinical evidence can restrict translation into reliable therapies. Liposomes, solid lipid nanoparticles, polymeric nanoparticles, and carefully evaluated combination approaches may offer useful research directions, but their value must be demonstrated through product-specific testing.

At present, the discussion should not be interpreted as evidence that these natural agents can replace rehydration, approved antimicrobial treatment, diagnostic testing, or professional care when indicated. The most appropriate conclusion is that standardized phytochemicals are research candidates whose role must be established by rigorous microbiological, pharmaceutical, toxicological, and clinical studies.

12.2 Recommendations

Use authenticated raw materials and validated analytical methods.

Report complete search strategies and study-selection numbers in future reviews.

Prioritize reproducible experiments with clinically relevant strains and controls.

Investigate local intestinal exposure as well as systemic pharmacokinetics.

Assess safety, interactions, and effects on beneficial microbiota.

Develop formulations only where they solve a clearly demonstrated stability or delivery problem.

Conduct ethically approved clinical trials before making treatment claims.

Promote patient education and responsible use of prescribed medicines.

12.3 Final perspective

Natural-product research is most valuable when traditional knowledge is combined with rigorous chemistry, microbiology, pharmaceutics, toxicology, and clinical science. The future of phytomedicine in gastrointestinal infections depends not simply on identifying active plants, but on producing reproducible products and demonstrating meaningful benefits and acceptable risks in patients.

LIST OF ABBREVIATIONS

Abbreviation	Meaning
AMR	Antimicrobial resistance
GIT	Gastrointestinal tract
MDR	Multidrug-resistant
MIC	Minimum inhibitory concentration
NF-κB	Nuclear factor kappa B
IL	Interleukin
TNF-α	Tumour necrosis factor alpha
QS	Quorum sensing
ATP	Adenosine triphosphate
SLN	Solid lipid nanoparticle

Abbreviation	Meaning
TCM	Traditional Chinese Medicine
GI	Gastrointestinal
QC	Quality control
RCT	Randomized controlled trial

Note: Abbreviations are used for readability. Mechanistic descriptions in this report represent pathways proposed or discussed in the supplied review article and should be interpreted in light of the strength of the underlying evidence.

REFERENCES

1. Paterson D. L. Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: challenges and innovations in bacteriophage and probiotic treatments. Frontiers in Antibiotics. 2024; 3 (2):112–125.
2. Ahirwar P, Khare B, Jain PK, Jain A, Khan R, Thakur B. Compressive review on role of ICH guidelines in registration of pharmaceutical products. Asian Journal of Dental and Health Sciences. 2022; 2 (3):16–22.
3. Yadav C, Vaishnav R, Goyal A. Aspects of pharmaceutical process validation: A review. International Journal of Pharmacy and Pharmaceutical Research. 2018; 14 (1):55–66.
4. Abu Reid IO, Bakheet SM. Analytical techniques for the determination of paracetamol and related degradants. Journal of Analytical Methods in Chemistry. 2025; 2025:4077188.
5. Khan H, Sebu, Gaur P, Kumar A, ur Rahman M. Pharmacy exit exam for the upliftment of profession of pharmacy practice in India: A review. International Journal of Pharma Professional's Research. 2023; 14 (4):107–115.
6. Kumar M, Prakash S, Riaz M. Traditional medicinal plants used in gastrointestinal disorders: an evidence-based review of phytochemistry, pharmacological mechanisms, and safety. International Journal of Pharmaceutical Sciences. 2024; 16 (2):45–58.
7. Tamboli A, Mule S. Review on natural and synthetic drugs used in gastrointestinal disorders. International Journal of Pharmacy and Pharmaceutical Research. 2023; 15 (2):88–97.
8. Rostami H, Ghoshal UC. A review of herbal treatment for functional gastrointestinal disorders and infection. Progress in Medicine and Molecular Biology. 2023; 6 (1):a0000346.
9. Karlowsky JA, Zhanel GG. Alternatives therapeutic approaches to conventional antibiotics. Journal of Antimicrobial Chemotherapy. 2022; 77 (12):3102–3115.
10. Singhal A, Bhatia S. Antibacterial activity of some Indian Ayurvedic preparations against enteric bacterial pathogens. Journal of Ethnopharmacology. 2012; 142 (3):703–712. Reference note: The list above reproduces the references supplied in the source review article, with minor typographic normalization. Their bibliographic details have not been independently verified in this project. The original review article itself is the primary source for the project's framing and selected compound descriptions.

HOW TO CITE: Chakresh Madhav Mishra, Pramod Kumar Mishra, Sujeet Pratap Singh, Dr. Tarkeshwar Prasad Shukla, Alternative Medicine Biomolecules in the Management of Gastrointestinal Tract Infections, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 11, 2474-2484. https://doi.org/10.5281/zenodo.24279311